Press "Enter" to skip to content
Indian Pharma Giant Dr. Reddy’s Laboratories launches anti depressant tablets in U.S.

Indian Pharma Giant Dr. Reddy’s Laboratories launches anti depressant tablets in U.S.

By Margarita Murphy on December 13, 2021

The company launched anti-depressant tablets in U.S. post approval given from US food and drug administration (FDA). The company has launched Venlafaxine ER in the US market. DR. Reddy’s product is equivalent to Venlafaxine Extended-Release, 150mg and 225mg, of Osmotica Pharmaceutical U.S. LLC. The Venlafaxine Extended-Release are used for treating major depressive disorder and social anxiety disorders.

The brand has recorded approx. $51 Million sales in last on year until October 2021. The company stated that the tablets are available in the US market in 150 mg and 225mg dose that are indicated for treating major depressive disorder and social anxiety disorder. The tablets are available in 30 and 90 count sizes, stated the company.

The product is a therapeutic equivalent generic version of Diovan (valsartan) tablets previously approved by US FDA. Valsartan is indicated to treat hypertension in adults of 6 and above age groups. The product intake reduces the occurrence of cardiovascular diseases preventing from fatality. Furthermore, in adults the tablet is found to treat heart failure reducing hospitalization resulting from heart failure. It also treats Post-mayocardial infraction.

The brand has recorded approx. $51 Million sales in last on year until October 2021. The company stated that the tablets are available in the US market in 150 mg and 225mg dose that are indicated for treating major depressive disorder and social anxiety disorder. The available in 30 and 90 count sizes, stated the company.

Published in News and Pharmaceuticals

Margarita Murphy

Her precision at work is well reflected in her unbeatable reporting style and flair for eloquent presentation. Given her educational background in Biopharmaceuticals which she completed from Rowan University, Margarita L. Murphy is a blend of both worlds with technical medical writing prowess, encompassing dexterity in a drug trial and regulatory documents, coupled with stark advertising skills to promote content on online news sites, encouraging a larger number of eye-balls. Owing to her previous job role as a trained medical writer in renowned drug companies as well as medical journals, Margarita is skilled in compliant writing and writes in several variants such as promotional content, FDA reports as well as medical journals, and investigator brochures.

More from NewsMore posts in News »
More from PharmaceuticalsMore posts in Pharmaceuticals »

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *